مصطلحات الفهرس: liver failure, pancreas cancer, pancreatitis, priority journal, quasi experimental study, randomized controlled trial (topic), review, side effect/si [Side Effect], systolic blood pressure, uncertainty, upper respiratory tract infection, urinary tract infection, albiglutide/cm [Drug Comparison], albiglutide/dt [Drug Therapy], albiglutide/pv [Special Situation for Pharmacovigilance], aleglitazar/cm [Drug Comparison], aleglitazar/dt [Drug Therapy], aleglitazar/pv [Special Situation for Pharmacovigilance], antidiabetic agent/ae [Adverse Drug Reaction], antidiabetic agent/cb [Drug Combination], antidiabetic agent/dt [Drug Therapy], antidiabetic agent/pv [Special Situation for Pharmacovigilance], creatinine/ec [Endogenous Compound], dipeptidyl peptidase IV inhibitor/cm [Drug Comparison], dipeptidyl peptidase IV inhibitor/dt [Drug Therapy], dipeptidyl peptidase IV inhibitor/pv [Special Situation for Pharmacovigilance], glipizide/cm [Drug Comparison], glipizide/dt [Drug Therapy], glipizide/pv [Special Situation for Pharmacovigilance], glitazar derivative/cm [Drug Comparison], glitazar derivative/dt [Drug Therapy], glitazar derivative/pv [Special Situation for Pharmacovigilance], glitazone derivative/cb [Drug Combination], glitazone derivative/cm [Drug Comparison], glitazone derivative/dt [Drug Therapy], glitazone derivative/pv [Special Situation for Pharmacovigilance], glucagon like peptide 1 receptor agonist/cm [Drug Comparison], glucagon like peptide 1 receptor agonist/dt [Drug Therapy], glucagon like peptide 1 receptor agonist/pv [Special Situation for Pharmacovigilance], hemoglobin A1c/ec [Endogenous Compound], insulin/ae [Adverse Drug Reaction], insulin/cm [Drug Comparison], insulin/dt [Drug Therapy], insulin/pv [Special Situation for Pharmacovigilance], linagliptin/cm [Drug Comparison], linagliptin/dt [Drug Therapy], linagliptin/pv [Special Situation for Pharmacovigilance], pioglitazone/cm [Drug Comparison], pioglitazone/dt [Drug Therapy], pioglitazone/pv [Special Situation for Pharmacovigilance], placebo, sitagliptin/cm [Drug Comparison], sitagliptin/dt [Drug Therapy], sitagliptin/pv [Special Situation for Pharmacovigilance], sodium glucose cotransporter 2 inhibitor/cm [Drug Comparison], sodium glucose cotransporter 2 inhibitor/pv [Special Situation for Pharmacovigilance], vildagliptin/cm [Drug Comparison], vildagliptin/dt [Drug Therapy], vildagliptin/pv [Special Situation for Pharmacovigilance], voglibose/cm [Drug Comparison], voglibose/dt [Drug Therapy], voglibose/pv [Special Situation for Pharmacovigilance], sodium glucose cotransporter 2 inhibitor/dt [Drug Therapy], acute kidney failure, adverse drug reaction, albuminuria, body weight, cardiovascular mortality, chronic kidney failure, creatinine blood level, diabetes mellitus/dt [Drug Therapy], diabetic ketoacidosis, diastolic blood pressure, drug efficacy, drug safety, end stage renal disease, estimated glomerular filtration rate, evidence based medicine, fracture, genital tract infection, glucose blood level, heart failure, hemoglobin blood level, human, hyperkalemia, hypoglycemia, hypovolemia, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handleTest/1/37083
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: liver failure, pancreas cancer, pancreatitis, priority journal, quasi experimental study, randomized controlled trial (topic), review, side effect/si [Side Effect], systolic blood pressure, uncertainty, upper respiratory tract infection, urinary tract infection, albiglutide/cm [Drug Comparison], albiglutide/dt [Drug Therapy], albiglutide/pv [Special Situation for Pharmacovigilance], aleglitazar/cm [Drug Comparison], aleglitazar/dt [Drug Therapy], aleglitazar/pv [Special Situation for Pharmacovigilance], antidiabetic agent/ae [Adverse Drug Reaction], antidiabetic agent/cb [Drug Combination], antidiabetic agent/dt [Drug Therapy], antidiabetic agent/pv [Special Situation for Pharmacovigilance], creatinine/ec [Endogenous Compound], dipeptidyl peptidase IV inhibitor/cm [Drug Comparison], dipeptidyl peptidase IV inhibitor/dt [Drug Therapy], dipeptidyl peptidase IV inhibitor/pv [Special Situation for Pharmacovigilance], glipizide/cm [Drug Comparison], glipizide/dt [Drug Therapy], glipizide/pv [Special Situation for Pharmacovigilance], glitazar derivative/cm [Drug Comparison], glitazar derivative/dt [Drug Therapy], glitazar derivative/pv [Special Situation for Pharmacovigilance], glitazone derivative/cb [Drug Combination], glitazone derivative/cm [Drug Comparison], glitazone derivative/dt [Drug Therapy], glitazone derivative/pv [Special Situation for Pharmacovigilance], glucagon like peptide 1 receptor agonist/cm [Drug Comparison], glucagon like peptide 1 receptor agonist/dt [Drug Therapy], glucagon like peptide 1 receptor agonist/pv [Special Situation for Pharmacovigilance], hemoglobin A1c/ec [Endogenous Compound], insulin/ae [Adverse Drug Reaction], insulin/cm [Drug Comparison], insulin/dt [Drug Therapy], insulin/pv [Special Situation for Pharmacovigilance], linagliptin/cm [Drug Comparison], linagliptin/dt [Drug Therapy], linagliptin/pv [Special Situation for Pharmacovigilance], pioglitazone/cm [Drug Comparison], pioglitazone/dt [Drug Therapy], pioglitazone/pv [Special Situation for Pharmacovigilance], placebo, sitagliptin/cm [Drug Comparison], sitagliptin/dt [Drug Therapy], sitagliptin/pv [Special Situation for Pharmacovigilance], sodium glucose cotransporter 2 inhibitor/cm [Drug Comparison], sodium glucose cotransporter 2 inhibitor/pv [Special Situation for Pharmacovigilance], vildagliptin/cm [Drug Comparison], vildagliptin/dt [Drug Therapy], vildagliptin/pv [Special Situation for Pharmacovigilance], voglibose/cm [Drug Comparison], voglibose/dt [Drug Therapy], voglibose/pv [Special Situation for Pharmacovigilance], sodium glucose cotransporter 2 inhibitor/dt [Drug Therapy], acute kidney failure, adverse drug reaction, albuminuria, body weight, cardiovascular mortality, chronic kidney failure, creatinine blood level, diabetes mellitus/dt [Drug Therapy], diabetic ketoacidosis, diastolic blood pressure, drug efficacy, drug safety, end stage renal disease, estimated glomerular filtration rate, evidence based medicine, fracture, genital tract infection, glucose blood level, heart failure, hemoglobin blood level, human, hyperkalemia, hypoglycemia, hypovolemia, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handleTest/1/37083
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المصدر: Heinsen , L J , Pararajasingam , G , Andersen , T R , Auscher , S , Sheta , H M , Precht , H , Engdam , K B , Hangaard , J , Lambrechtsen , J , Knop , F K & Egstrup , K 2023 , ' Liraglutide treatment is associated with progression of coronary artery fibrous plaque : a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes ' , BMC Cardiovascular Disorders , vol. 23 , no. 1 , 214 .

مصطلحات الفهرس: Coronary atherosclerosis, Coronary computed tomography angiography, Glucagon-like peptide 1 receptor agonist, Liraglutide, Type 2 diabetes mellitus, article

URL: https://curis.ku.dk/portal/da/publications/liraglutide-treatment-is-associated-with-progression-of-coronary-artery-fibrous-plaqueTest(9ea1338b-8c30-4917-bd00-8f9ca7f4bc92).html
https://doi.org/10.1186/s12872-023-03228-5Test
https://curis.ku.dk/ws/files/372704186/s12872_023_03228_5.pdfTest

المصدر: Longo , M , Di Meo , I , Caruso , P , Muscio , M F , Scappaticcio , L , Maio , A , Maiorino , M I , Bellastella , G , Signoriello , G , Knop , F K , Rizzo , M R & Esposito , K 2023 , ' Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes ' , Diabetes Research and Clinical Practice , vol. 200 , 110688 .

مصطلحات الفهرس: Cognitive function, Elderly patients, Endothelial progenitor cells, EPCs, GLP-1RA, Glucagon-like peptide 1 receptor agonists, Metformin, Type 2 diabetes, article

URL: https://curis.ku.dk/portal/da/publications/circulating-levels-of-endothelial-progenitor-cells-are-associated-with-better-cognitive-function-in-older-adults-with-glucagonlikeTest-peptide-1-receptor-agonisttreated-type-2-diabetes(896e9118-e628-423d-9a32-53f199dd342e).html
https://doi.org/10.1016/j.diabres.2023.110688Test
https://curis.ku.dk/ws/files/365665995/1_s2.0_S0168822723004497_main.pdfTest

المؤلفون: Mottl, Amy K

المصدر: American journal of kidney diseases : the official journal of the National Kidney Foundation; vol 79, iss 4, 457-479; 0272-6386

مصطلحات الفهرس: Kidney, Humans, Diabetes Mellitus, Hypoglycemic Agents, Nephrology, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Diabetes, SGLT2 inhibitors, blood pressure control, chronic kidney disease, commentary, evidence-based recommendation, glucagon-like peptide 1 receptor agonists, glycemic targets, guideline implementation, guidelines, metformin, nephrology best practices, physical activity, protein intake, smoking, sodium intake, Health Services, Clinical Research, Comparative Effectiveness Research, Prevention, Kidney Disease, Patient Safety, Renal and urogenital, Metabolic and endocrine, Good Health and Well Being, Clinical Sciences, Public Health and Health Services, Urology & Nephrology, article

URL: https://escholarship.org/uc/item/8qn660xvTest
https://escholarship.orgTest/

المؤلفون: Talha, Khawaja M

المصدر: Methodist DeBakey cardiovascular journal; vol 18, iss 5, 40-53; 1947-6094

مصطلحات الفهرس: Humans, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucose, Pharmaceutical Preparations, Hypoglycemic Agents, Heart Failure, Randomized Controlled Trials as Topic, Observational Studies as Topic, cardiovascular disease, glucagon-like peptide 1 receptor agonist, heart failure, prevention, sodium-glucose cotransporter-2 inhibitor, Diabetes, Clinical Trials and Supportive Activities, Heart Disease, Cardiovascular, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Metabolic and endocrine, Good Health and Well Being, article

URL: https://escholarship.org/uc/item/3rv702wtTest
https://escholarship.orgTest/

المصدر: Jensen , D M , Skovsted , G F , Bonde , M F B , Bentzon , J F , Rolin , B , Franck , G , Ougaard , M K E , Voetmann , L M , Bachmann , J C , Uryga , A , Pyke , C , Kirk , R K , Hvid , H , Knudsen , L B , Lykkesfeldt , J & Nyberg , M 2022 , ' Semaglutide treatment attenuates vessel remodelling in ApoE−/− mice following vascular injury and blood flow perturbation ' , Atherosclerosis Plus , vol. 49 , pp. 32-41 .

مصطلحات الفهرس: Atherosclerosis, Glucagon-like peptide 1 receptor agonists, Phenotypic switching, Plaque erosion, Semaglutide, Vascular injury, Vascular smooth muscle cells, article

URL: https://curis.ku.dk/portal/da/publications/semaglutide-treatment-attenuates-vessel-remodelling-in-apoe-mice-following-vascular-injury-and-blood-flow-perturbationTest(966738ce-8b91-4e3a-9c31-806e569427c3).html
https://doi.org/10.1016/j.athplu.2022.05.004Test
https://curis.ku.dk/ws/files/313496733/1_s2.0_S2667089522000165_main.pdfTest

مصطلحات الفهرس: American Diabetes Association (ADA), Xultophy (IDegLira), Insulin Degludec/Liraglutide, Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), diabetic kidney disease (DKD), Daily Profile Of Blood Glucose, Journal Article, VoR

URL: http://repo.lib.tokushima-u.ac.jp/116818Test
http://repo.lib.tokushima-u.ac.jp/files/public/11/116818/20220318163106726965/ijed_5_1_129.pdfTest
https://doi.org/10.36266/IJED/129Test
https://doi.org/10.36266/IJED/129Test

مصطلحات الفهرس: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), Oral semaglutide (Rybelsus), Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), Fasting time period, Journal Article, VoR

URL: http://repo.lib.tokushima-u.ac.jp/116924Test
http://repo.lib.tokushima-u.ac.jp/files/public/11/116924/20220420131308625064/srmcr_3_1_150.pdfTest
https://doi.org/10.51737/2766-4813.2022.050Test
https://doi.org/10.51737/2766-4813.2022.050Test

مصطلحات الفهرس: Glucagon-like peptide 1 receptor agonist (GLP-1RA), Oral semaglutide (Rybelsus), Oral hypoglycemic agents (OHAs), Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), Japan LCD promotion association (JLCDPA), Journal Article, VoR

URL: http://repo.lib.tokushima-u.ac.jp/116923Test
http://repo.lib.tokushima-u.ac.jp/files/public/11/116923/20220420115143420566/srcri_3_1_143.pdfTest
https://doi.org/10.51737/2766-4589.2022.043Test
https://doi.org/10.51737/2766-4589.2022.043Test